Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx SANTA CLARA, Calif., September 22, 2017 Agilent Technologies Inc. (NYSE: A) today announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by U.S. Food and Drug... Read more